Genomma gets a cash injection
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Mexican OTC medicines and personalcare specialist Genomma Lab has secured an investment package of almost US$100 million (€85 million) to help fund the ongoing construction of a production plant in its home country.
You may also be interested in...
$60m For Mexico’s Genomma From World Bank Group’s Private Sector Arm
IFC, the private sector arm of the World Bank Group, has loaned $60m to Mexican Pharmaceutical Genomma, building on its long track record in Latin American health investments.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.